PMID: 11325452Apr 28, 2001Paper

Local control of T3N0 glottic carcinoma by 60 Gy given over five weeks in 2.4 Gy daily fractions. One more point on the biological effective dose (BED) curve

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
S M JacksonA D Flores

Abstract

Seventy patients with T3N0 glottic cancer who received a total dose of 60 Gy in twenty-five 2.4 Gy daily fractions over 5 weeks had an initial post radiation primary recurrence free rate of 65% at 5 years. This provides one more point for the dose response for T3 glottic cancer Radiother Oncol (1999) 15.

References

Aug 1, 1989·The British Journal of Radiology·J F Fowler
Oct 15, 1995·International Journal of Radiation Oncology, Biology, Physics·H R WithersN Gupta
Apr 1, 1997·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·S M JacksonJ S Durham
Oct 27, 1998·International Journal of Radiation Oncology, Biology, Physics·J C van der VoetH Bartelink
Aug 6, 1999·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·S M JacksonB Baerg
Jan 7, 2000·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J P WylieN J Slevin

❮ Previous
Next ❯

Citations

Mar 31, 2015·European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·Dimitrios PantazisMaria Riga
Sep 14, 2017·Journal of Radiation Research·Hideya YamazakiKazuhiko Ogawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.